SURMOUNT-1 enrolled 2,539 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition
SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy
With careful planning, gradual dosing, and regular check-ins with your healthcare provider, the transition can be smooth and productive
Overdosage In the event of an overdosage, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations
Understanding the broader peptide landscape helps researchers make informed decisions about their supplier relationships
For South Indian breakfasts, one idli with coconut chutney still satisfies